Methodology and Economics

Pheby, John; Phelby, John

doi:10.4324/9781315702421

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Three-year overall survival (OS) was calculated on a time-since-diagnosis scale, with the date of diagnosis defined per the European Network for Cancer Registries recommendations (eMethods 2 in Supplement 1). Time-at-risk commenced on the date of (1) baseline interview or (2) diagnosis, whichever was later, and ended on the date of (1) death, (2) when the patient was last known to be alive, or (3) 3 years after diagnosis, whichever came first. We performed survival analyses by population group and macroregion of residence using Cox regression models.…”

Section: Methodsmentioning

confidence: 90%

Analysis of the Breast Cancer Journey in Namibia

Boucheron,

Zietsman,

Pontac

et al. 2023

JAMA Netw Open

View full text Add to dashboard Cite

ImportanceBreast cancer (BC) is the leading cancer among women in Namibia. Examining the BC journey in this multiracial country where inequalities remain large is needed to inform effective interventions to reduce BC mortality.ObjectiveTo describe the entire BC journey of Namibian women by race, utilizing the World Health Organization Global Breast Cancer Initiative (GBCI) framework.Design, Setting, and ParticipantsThis cohort study used the Namibian subset of the African Breast Cancer–Disparities in Outcomes prospective cohort. Participants were all Namibian residents with confirmed incident BC who presented at the main national public oncology center of the Windhoek Central Hospital (WCH). Follow-up started from recruitment (September 8, 2014, to October 5, 2016) and ended up to 3 years after diagnosis (December 13, 2014, to September 27, 2019). Data analysis was conducted from June 2022 to August 2023.ExposuresParticipants’ self-reported ethnicities were aggregated into 3 population groups: Black, mixed ancestry, and White.Main Outcomes and MeasuresThree-year overall survival (OS) was examined using Cox models, and summary statistics were used to describe women’s BC journey, including GBCI pillar key performance indicators: (1) early stage (TNM I or II) diagnosis (population benchmark ≥60%), (2) prompt diagnosis, ie, 60 days or less to first health care practitioner visit (population benchmark 100%), and (3) completion of recommended multimodal treatment (MT, ie, surgery plus chemotherapy) (population benchmark ≥80%).ResultsOf 405 women, there were 300 (74%) Black (mean [SD] age, 53 [15] years), 49 (12%) mixed ancestry (mean [SD] age, 53 [7] years), and 56 (14%) White (mean [SD] age, 59 [12] years) patients. Three-year OS was lowest in Black women (60% [95% CI, 54%-66%]; mixed ancestry: 80% [95% CI, 65%-89%]; White: 89% [95% CI, 77%-95%]), who had lower prevalence of early stage diagnosis (Black: 37% [95% CI, 31%-42%]; mixed ancestry and White: 75% [95% CI, 66%-83%]) and timely diagnosis (Black: 60% [95% CI, 54%-66%]; mixed ancestry and White: 77% [95% CI, 69%-85%]), while MT completion (Black: 53% [95% CI, 46%-59%]; mixed ancestry and White: 63% [95% CI, 50%-73%]) was low in all women.Conclusions and RelevanceIn this cohort study of 405 Namibian residents with BC, marked racial disparities in survival were paralleled by inequities all along the BC journey. To improve BC survival, interventions are needed to promote earlier diagnosis in Black Namibian women and to increase MT initiation and completion in all women.

show abstract

Section: Methodsmentioning

confidence: 90%